Print this page
-
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
Protocol: 012108Principal Investigator:
- Yun Kyoung Tiger (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Testing of Immune Synapse Characteristics During Therapy of Multiple Myeloma
Protocol: 012322Principal Investigator:
- Mansi Shah MD (Rutgers University)
Applicable Disease Sites: Multiple Myeloma -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Protocol: 012313Principal Investigator:
- Amer Assal MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma -
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
Protocol: 012314Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lymphoid Leukemia -
Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/ daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Protocol: 022305Principal Investigator:
- Neil Palmisiano MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Phase 3 Randomized Clinical Study of MK-4280A Coformulated Favezelimab MK-4280 plus Pembrolizumab MK-3475 Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008).
Protocol: 012315Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Hodgkin's Lymphoma